

Supplementary figures to:

2-Desaza-annomontine impedes angiogenesis through reduced VEGFR2 expression derived from inhibition of CDC2-like kinases.

Zech, T. J.¹; Wolf, A.^{2,3}; Hector, M.²; Bischoff-Kont, I.¹; Krishnathas, G. M.¹; Kuntschar, S.⁴; Schmid, T.⁴; Bracher, F.⁵; Langmann, T.^{2,3}; Fürst, R.^{1,6}

¹ Institute for Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe-University of Frankfurt, Frankfurt, Germany

² Laboratory for Experimental Immunology of the Eye, Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany


³ Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany

⁴ Institute of Biochemistry I, Faculty of Medicine, Goethe-University of Frankfurt, Frankfurt, Germany


⁵ Pharmaceutical Chemistry, Department of Pharmacy – Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany

⁶ Pharmaceutical Biology, Department of Pharmacy – Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany


For correspondence, please contact Prof. Robert Fürst, Pharmaceutical Biology, Department of Pharmacy – Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany
Robert.Fuerst@cup.uni-muenchen.de



C81




MU1210




T3-CLK

Supplementary Fig. 1 Structures of C81, MU1210 and T3 CLK
Structures were drawn using ChemSketch (ACD/Labs).




Supplementary Fig. 2 Laser spot size in CNV model

a/e Representative infrared (IR) fundus images at indicated time points and treatments post laser injury. Lower panel shows OCT scan from one laser spot. Scale bar: 200 μm. **b-d/f-h** Quantification of laser spot size. **b-d** n = 19-25 eyes, **f-h** n = 10-15 eyes. Data show mean ± SD, two-tailed unpaired Student's t test; *p ≤ 0.05






Supplementary Fig. 3 Effect of C81 on proliferation chemotactic migration and tube formation of HUVECs

a Quantification of proliferation of HUVECs in a crystal violet assay. **b** Distribution of HUVECs in the indicated stages of the cell cycle quantified through Propidium iodide staining and Flow cytometry. **c** quantification of migration of HUVECs along a 0-20 % FCS gradient by crystal violet staining. **d** Quantification of directedness, forward migration index in parallel to the chemoattractant, accumulated distance, Euclidian distance, and velocity of scarcely seeded HUVECs along a 0-20 % FCS gradient over 20 h. **e/f** Quantification of tube formation for number of junctions (**e**) or number of master segments (**f**). **g** representative images of HUVEC tubes on Matrigel. **a-d/e/f** Data show mean ± SD, **a** IC₅₀ was calculated using a nonlinear regression with a variable slope **b/d** two-way ANOVA with Dunnett's post hoc test testing for a simple effect within cell cycle stages (**b**) or mode of quantification (**d**). **c/e/f** One-way ANOVA with Dunnett's post hoc analysis comparing treatments and no-gradient control vs vehicle control (**c**) or comparing treatments to vehicle control (**e/f**). *p ≤ 0.05 vs vehicle control within cell cycle stage (**b**), vehicle control (**c/e/f**) or mode of quantification (**d**). **g** Scalebar represents 100 μm.




Supplementary Fig. 4 C81 inhibits angiogenic key steps *in vitro* in HMEC-1

a/b Quantification of HMEC-1 spheroids pretreated for 30 min with the indicated concentrations of C81/vehicle control and stimulated with VEGF for 20 h for accumulated sprouting length per spheroid (**a**) and number of sprouts per spheroid (**b**). **c** Representative images of collagen embedded HMEC-1 spheroids at the end of treatment. **d** Quantification of scratches for closed surface area under treatment of C81, negative ctrl served as a baseline. **e** Representative images of scratches after incubation. **f** Quantification of proliferation of HMEC-1 in a crystal violet assay


Donor 1**Donor 2****Donor 3****Supplementary Fig. 5 Unedited images of IGCs in HUVECs**

Immunofluorescence pictures of HUVECs stained with Hoechst 33342 for the nuclei and anti-p-SR proteins to mark interchromatin granule clusters. Altered distribution can be observed when HUVECs are treated with C81 or MU1210 for 6 h.




Supplementary Fig. 6 Quantification of CLK1-4 knockdowns and additional quantification of knockdown spheroids

a-d Relative quantification of CLK1-4 mRNA expression, normalized to GAPDH, 72 h after the indicated knockdown was induced in HUVECs. **e-h** Quantification of HUVEC spheroids embedded into collagen 72 h after the indicated knockdown was induced, pretreated for 30 min with the indicated concentrations of C81/vehicle control and stimulated with VEGF for 20 h for number of sprouts per spheroid. **a-h** Data are represented as mean \pm SD, $n = 3$ donors (**a-e/g**) or $n = 4$ donors (**f/h**). **a-d** unpaired student's t-test; **e-h** one-way ANOVA with Tuckey's post hoc test. **a-h** * $p \leq 0.05$ compared to non-targeting control (**a-d**) or VEGF non targeting control (**e-h**); **e-h** # $p \leq 0.05$ compared to knockdown cells stimulated with VEGF, only used to compare treatments of knockdown cells.



Supplementary Fig. 7 RNA-Seq of C81 treated cells detects multiple affected biological processes, and notably WNT/ β -catenin as an affected signaling pathway

GO-Term analysis of biological processes affected by 6 h treatment of HUVECs with 10 μ M C81 compared to vehicle control, detected using short read RNA-Seq. N = 3 donors.



Supplementary Fig. 8 β -Catenin knockdown efficiency

Semiquantitative analysis of β -catenin protein expression, normalized to β -actin, using densitometry in Fiji/ImageJ in HUVECs 48 h after knockdown was induced. C81 was added for the final 10 h of the incubation. Data are depicted as mean \pm SD, one-way ANOVA with Dunnett's post hoc test, * $p \leq 0.05$ compared to the non-targeting control.